Exchange: NASDAQ·Updated 06:26 PM EDT

TENK TenX Keane Acquisition

$0.8684
$0.0678
(8.56%)
Today
Closed $0.86
$0.0084
(0.98%)
After Hours
Mkt Cap$73.66M
Vol54,756.00

About TENK

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
58

Bullish Sentiment

How do you feel about TENK?

Advertisement|Remove ads.